The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study

BACKGROUND: Levodopa–carbidopa intestinal gel (LCIG) treatment, a unique drug delivery system for patients with advanced Parkinson’s disease (PD), is covered by health insurance in Japan since September 2016. Various LCIG procedure/device-associated adverse events (AEs) have been reported; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Kanefumi, Yube, Yukinori, Yamazaki, Yukinao, Fukuchi, Takehide, Kato, Masaki, Koike, Tomoyuki, Uehara, Takeshi, Ikeda, Yoshiou, Furune, Satoshi, Murakami, Hidehiro, Kubota, Eiji, Fujioka, Shinsuke, Sato, Yoshinori, Jin, Xiaoyi, Suzuki, Tomohiko, Furukawa, Kazuhiro, Tsuboi, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228941/
https://www.ncbi.nlm.nih.gov/pubmed/34172002
http://dx.doi.org/10.1186/s12883-021-02269-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228941/
https://www.ncbi.nlm.nih.gov/pubmed/34172002
http://dx.doi.org/10.1186/s12883-021-02269-7

Ejemplares similares